Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share, while projecting moderate sales growth of 2.5% to 4.5% for 2026. Despite reporting $2.24 billion in sales last quarter, the company faced a significant bottom-line dip of 41.8% due to order cancellations in emerging markets, leading to a 15% decline in stock price. Analysts continue to maintain a 'Buy' rating amid these challenges, citing the potential for Zimmer Biomet to bolster its shares through improving free cash flow and planned share buybacks.
“Zimmer Biomet Holdings, Inc. · announced · quarterly cash dividend · $0.24 per share”
“Zimmer Biomet · is a · global medical technology leader · true”
“Zimmer Biomet · operates in · 25+ countries · true”
“Zimmer Biomet · has sales in · 100+ countries · true”
“Zimmer Biomet · will unveil · new clinical and operational data · true”
“Zimmer Biomet · offers · the industry's most comprehensive and adaptable suite of orthopedic robotics and navigation technologies · true”
“Zimmer Biomet · has · a comprehensive portfolio designed to maximize mobility and improve health · true”
“Zimmer Biomet · is · a global medical technology leader · with a comprehensive portfolio designed to maximize mobility and improve health”
“Zimmer Biomet · has · 90+ years of trusted leadership · and proven expertise”
“Zimmer Biomet · is one of · 10 high-quality companies · best stocks to buy for 2026”
“Zimmer Biomet · reported profits of · $139.3 million · 70¢ per share”
“Zimmer Biomet · reported sales of · $2.24 billion · for the three months ended Dec. 31, 2025”